Stock Analiz

Viemed Healthcare, Inc. VMD

Misc Health and Biotechnology Services · data as of November 13, 2026

$9.17Market cap $347M
Open the interactive analysis →

Viemed Healthcare, Inc. (VMD) is a healthcare company listed in the US with a market value of about $347M. In the twelve months to September 30, 2026 it had revenue of $310M and net income of $16M, a net margin of 5.0%.

Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is future growth (5/5); the weakest is track record (2/5).

Key numbers: a P/E of 24.1, a price to free cash flow of 16.3, 5-year revenue growth of 16% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 11% below the current price.

About Viemed Healthcare

Viemed Healthcare is listed in the US and classified in misc health and biotechnology services. Revenue went from $64M in 2018 to $270M in 2025, growth of about 22.7% a year. It was profitable in 8 of the last 8 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 1% of revenue on research and development.

Score: 3.4 / 5

Value3/5
Future growth5/5
Track record2/5
Financial health5/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • ROE above 15%
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • Dividend 3 years in a row

Valuation

P/E (TTM)24.1
Forward P/E18.0
P/FCF16.3
P/S1.1
P/B2.3
EV/EBITDA6.4
PEG—
Dividend yield0.00%
FCF yield6.2%
Shareholder yield3.8%
Intrinsic value vs. price−11%

Growth and quality

Revenue growth (1 yr)20.5%
Revenue growth (5 yrs, per year)15.5%
EPS growth (5 yrs, per year)-13.9%
FCF growth (3 yrs, per year)35.0%
Net margin (5-yr avg.)5.7%
ROIC (5-yr avg.)8.4%
Profitable years (of last 10)8
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$310M$270M$224M$183M$139M$117M$131M$80M$64M
Net income$16M$15M$11M$10M$6M$9M$32M$9M$10M
Free cash flow$21M$12M$1M$19M$5M$3M$22M$6M$16M
EPS (diluted)$0.38$0.37$0.28$0.25$0.16$0.22$0.78$0.21$0.24
Net margin5.0%5.5%5.0%5.6%4.5%7.8%24.0%10.6%14.8%
ROIC—10.3%9.1%8.2%5.8%8.4%23.7%16.2%30.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $12.00, 31% above the current price; targets range from $10.00 to $14.00; the consensus rating is “Buy”; expected EPS is $0.40 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Viemed Healthcare’s P/E ratio?

About 24.1, based on the last twelve months of diluted earnings per share (forward P/E about 18.0).

Is Viemed Healthcare stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 11% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Viemed Healthcare pay a dividend?

Not currently.

Is Viemed Healthcare a good stock to buy?

We do not give buy or sell advice. Viemed Healthcare scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.